Compounded vs. Brand-Name GLP-1 Medications: A Side-by-Side Comparison (2026)
Wegovy, Ozempic, Mounjaro, and Zepbound are FDA-approved brand-name medications from Novo Nordisk and Eli Lilly. New Hope Weight Loss dispenses compounded semaglutide and tirzepatide from licensed 503(a) pharmacies. They contain the same active ingredients but are not legally the same products. Here's the honest, side-by-side look.
The big-picture comparison
| Dimension | Compounded Semaglutide / Tirzepatide (NHWL) |
Brand-Name (Wegovy, Ozempic, Mounjaro, Zepbound) |
|---|---|---|
| Active ingredient | Semaglutide (GLP-1) or Tirzepatide (GLP-1/GIP) | Semaglutide (Wegovy / Ozempic) or Tirzepatide (Mounjaro / Zepbound) |
| Manufacturer | Licensed 503(a) compounding pharmacy | Novo Nordisk or Eli Lilly |
| Regulatory status | Patient-specific compound; pharmacy state-licensed; APIs FDA-registered. Not an FDA-approved finished drug. | FDA-approved finished drug. |
| Cash price (no insurance) | $166/mo (semaglutide) or $233/mo (tirzepatide), 90-day program | ~$1,069 – $1,349/mo (Wegovy / Ozempic / Mounjaro / Zepbound list price) |
| Includes physician oversight? | ✓ Initial visit + ongoing labs and dose adjustments included | Depends on prescriber — separate office visit fees apply |
| Includes B12 / lipotropic add-ons? | ✓ Available; commonly part of the formulation | ✗ Not part of the brand-name product |
| Insurance coverage | ✗ Generally not covered. HSA/FSA usually eligible. | Sometimes covered with prior authorization (30–90 day wait, ~40% denial rate) |
| Form factor | Vial + syringe; doses titrated individually | Pre-filled pen, fixed step doses |
| Supply consistency | Stable post-shortage; physician dispensing | Subject to manufacturer shortage cycles (resolved Feb 2025; supply now stable) |
| Counterfeit risk | Low at reputable 503(a). High at offshore "research peptide" vendors — avoid. | Low when filled at a U.S. retail pharmacy; high if bought online from non-U.S. sources. |
| Where you can get it | NHWL Costa Mesa or telemedicine across California | Any U.S. retail pharmacy with a brand-name prescription |
What's the same
- The active ingredient. Semaglutide is semaglutide; tirzepatide is tirzepatide. Whether dispensed in a Wegovy pen or a 5 mL vial from a 503(a) pharmacy, the molecule is the same when sourced from a reputable supplier.
- The mechanism. GLP-1 receptor agonism, gastric emptying delay, hypothalamic appetite reduction, and reward-circuit modulation all happen the same way regardless of the finished product.
- The clinical effect. Patients on properly dosed compounded semaglutide and patients on Wegovy follow similar weight-loss curves in our clinic.
What's different
- Regulatory pathway. Brand-name = FDA-approved finished drug. Compounded = patient-specific preparation by a licensed pharmacy under section 503(a) of the FD&C Act.
- Price. Compounded is approximately one-fifth to one-eighth the cash price of brand-name.
- Form. Pre-filled pen vs. vial + syringe. Pen is more convenient. Vial allows individualized titration that the pen's fixed step doses don't.
- Excipients. Brand-name is standardized to the FDA label. Compounded preparations vary by pharmacy — B12 and lipotropic combinations are common.
- Availability of a Certificate of Analysis (COA). NHWL's 503(a) supplier provides COA on request, documenting potency and sterility for each batch.
The 2026 regulatory context (so you understand the landscape)
The FDA-declared shortage of brand-name semaglutide ended in February 2025; tirzepatide ended in December 2024. The 503A grace period ended April 22, 2025; 503B grace period ended May 22, 2025. On April 30, 2026 the FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — public comment open through June 29, 2026.
503A patient-specific compounding remains legal when the compound is not a duplicate of an FDA-approved drug under the FDA's interpretation of section 503A. The standard pathway: a different dose, different concentration, or an additional clinically meaningful ingredient (e.g., B12) creating a distinct preparation tailored to the patient. NHWL operates exclusively under this 503A pathway.
When brand-name is the right choice
We're a compounded-medication clinic and we'll still recommend brand-name when it fits:
- Your insurance covers Wegovy, Zepbound, Ozempic, or Mounjaro for your indication and your out-of-pocket is comparable.
- You have type 2 diabetes and your endocrinologist is managing care with brand-name GLP-1.
- You're enrolled in a clinical trial of a specific brand-name product.
- You have a documented allergy or sensitivity to a compounding excipient.
- You travel internationally frequently and prefer commercial packaging documentation.
When compounded is a reasonable choice
- You don't have insurance coverage for brand-name and ~$1,349/month cash isn't realistic.
- You want individualized dose titration the brand-name pen's fixed step doses don't allow.
- You want bundled physician oversight, labs, and dose adjustments without separate office-visit fees.
- You want B12 / lipotropic add-ons in the same protocol.
Red flags when shopping for compounded GLP-1 anywhere
- No physician consultation before prescription.
- Pharmacy name not disclosed.
- "Research peptide" or "not for human use" labeling.
- No batch number or COA available.
- No follow-up or dose-titration schedule.
- Marketing that claims equivalence to or replacement of brand-name drugs ("just like Ozempic," "the same as Wegovy"). Equivalence claims are not legally defensible and are a marker of careless practice.
Frequently asked questions
Is compounded semaglutide the same as Wegovy or Ozempic?
No. Same active ingredient (semaglutide), different products. Brand-name Wegovy and Ozempic are FDA-approved finished drugs from Novo Nordisk; compounded semaglutide is prepared by licensed 503(a) compounding pharmacies for individual patients. The chemistry of the molecule is the same; the regulatory pathway, manufacturer, and pricing differ.
Is compounded semaglutide still legal in 2026?
Yes, when prepared by a licensed 503(a) pharmacy for an individual patient under a valid prescription with a clinical justification documented (different dose, concentration, or added ingredient). The April 30, 2026 FDA proposal to remove semaglutide and tirzepatide from the 503B Bulks List does not affect 503A patient-specific compounding.
Why is compounded semaglutide so much cheaper than Wegovy?
Brand-name Wegovy at ~$1,349/month carries Novo Nordisk's research, marketing, regulatory, and patent costs. Compounded preparations don't carry those costs and are dispensed under a different legal framework. The active ingredient is the same molecule.
Are compounded medications safe?
Quality depends on the specific compounding pharmacy. Reputable state-licensed 503(a) pharmacies with sterile preparation, batch testing, and traceable APIs produce a high-quality product. Quality drops sharply with offshore peptide vendors. Always verify your physician sources from a state-licensed compounding pharmacy and request a Certificate of Analysis.
What's the difference between 503(a) and 503(b)?
503(a) pharmacies dispense to individual patients with prescriptions, state-licensed and inspected. 503(b) outsourcing facilities produce in larger batches under cGMP standards similar to drug manufacturing. NHWL works with 503(a) pharmacies.
Will my insurance cover this?
Generally, no — most insurance plans don't cover compounded GLP-1 medications. HSA and FSA accounts are usually eligible. We accept Klarna and Affirm financing if monthly payments help.
This page is informational only and not medical advice. Speak with a licensed physician before starting any GLP-1 therapy. Individual results vary. New Hope Weight Loss dispenses compounded semaglutide and compounded tirzepatide via state-licensed 503(a) pharmacies. We do not dispense Ozempic®, Wegovy®, Mounjaro®, or Zepbound® — those are brand-name FDA-approved medications manufactured by Novo Nordisk and Eli Lilly. Compounded medications are not FDA-approved products. Trade-name references on this page are for educational comparison only and do not imply equivalence, endorsement, or affiliation. Wegovy®, Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® are registered trademarks of Eli Lilly and Company.